Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305564 | 0.86 | HRH4 (0.57) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL27337665 | 0.84 | HRH4 (0.59) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL30310556 | 0.84 | HRH4 (0.56) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL29063451 | 0.84 | HRH4 (0.56) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL6171590 | 0.83 | MEN1 (0.56) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL17136028 | 0.81 | HSD17B10 (0.64) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL23835756 | 0.80 | HRH4 (0.56) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL16236158 | 0.80 | HRH4 (0.56) | HRH4DAOCA12CA9CDK1 | |
| SCHEMBL31392795 | 0.80 | KDM4E (0.58) | ALDH1A1KMT2AHRH4DAOKDM4E | |
| SCHEMBL24740173 | 0.80 | HRH4 (0.56) | HPGDHSD17B10MEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2149552-A1 | 5,6 substituted benzamide derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4660193-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-4536680-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | The Governors of the University of Alberta (CA) | 2025-04-16 | — | — | EP | disclosed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-1106800-A | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0234540-B1 | HEAT-SENSITIVE RECORDING MATERIAL | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4731353-A | METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER | KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) | 1988-03-15 | — | — | US | disclosed |
| EP-0234540-A2 | Heat-sensitive recording material | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-3983137-A | Process for preparing 3-(indol-3-yl)-dehydronaphthalide hydrochlorides | POLAROID CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3933854-A | CHEMICAL INTERMEDIATES FOR INDICATOR DYES | POLAROID CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | HPGD 3164/4885HSD17B10 856/4885MEN1 4346/4885 |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | HPGD 2276/4885HSD17B10 1041/4885MEN1 3229/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | HPGD 176/4885HSD17B10 297/4885MEN1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.